NCT01178827View on ClinicalTrials.gov

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Overactive Bladder
Interventions
DRUG

trospium chloride

trospium chloride (60mg) once daily for 10 days

DRUG

oxybutynin IR

oxybutynin IR (5 mg) three times daily for 2 days

DRUG

oxybutynin IR placebo

oxybutynin IR placebo three times daily for 2 days

Trial Locations (1)

Unknown

Salt Lake City

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY